Editorial

DOI: 10.4244/EIJ-E-25-00027

Antithrombotic strategies after TAVI in light of cerebral microembolism

George Dangas1, MD, PhD; Johny Nicolas1, MD, MSc

Transcatheter aortic valve implantation (TAVI) has transformed the treatment landscape of aortic stenosis. During the procedure, microembolisation of valve debris and foreign materials may occur, potentially resulting in subclinical cerebral abnormalities. Diffusion-weighted magnetic resonance imaging (DW-MRI) studies have shown new cerebral lesions in a significant proportion of TAVI patients1. Despite a substantial decline in overt stroke with newer-generation valves, cerebrovascular embolisation persists. Hence, the quest to mitigate post-TAVI stroke risk continues through cerebral embolic protection or antithrombotic strategies.

In this issue of EuroIntervention, Jimenez Diaz et al report on the results of the AUREA trial: a single-centre pilot study addressing an important gap by comparing dual antiplatelet therapy (DAPT) with oral anticoagulation (OAC) for reducing cerebral microembolism post-TAVI in patients without an indication for OAC. Patients were randomised to either DAPT or a vitamin K antagonist (VKA) for 3 months post-TAVI2. DW-MRI was performed at baseline and at 6 and 90 days after TAVI. Cerebral embolism was detected in over 75% of patients in both arms. While the number of lesions was similar, DAPT was associated with a significantly...

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 21 Number 13
Jul 7, 2025
Volume 21 Number 13
View full issue


Key metrics

Suggested by Cory

EXPERT REVIEW

10.4244/EIJ-D-18-00454 Sep 7, 2018
TAVI and the brain: update on definitions, evidence of neuroprotection and adjunctive pharmacotherapy
Lansky AJ et al
free

10.4244/EIJV9SSA9 Sep 15, 2013
Antithrombotic and antiplatelet therapy in TAVI patients: a fallow field?
Collet J and Montalescot G
free

Expert Review

10.4244/EIJ-D-23-01087 Jul 1, 2024
Cerebrovascular events after transcatheter aortic valve implantation
Reddy P et al
free

10.4244/EIJV8SQA11 Sep 30, 2012
Transcatheter aortic valve implantation and cerebrovascular accidents
Stortecky S et al
free

10.4244/EIJV11SWA28 Sep 17, 2015
Antithrombotic therapy in TAVI patients: changing concepts
Gargiulo G et al
free

10.4244/EIJV8I1A4 May 15, 2012
Embolic protection devices during TAVI – the “proof of the pudding”
Van Mieghem NM and Serruys PW
free

10.4244/EIJV15I7A102 Sep 20, 2019
Antithrombotic therapy after TAVI: where are we going?
Wilkins B et al
free

CLINICAL RESEARCH

10.4244/EIJV12I4A84 Jul 20, 2016
Filter-based cerebral embolic protection with transcatheter aortic valve implantation: the randomised MISTRAL-C trial
Van Mieghem NM et al
free

10.4244/EIJV11SWA7 Sep 17, 2015
Stroke prevention in valvular heart disease: from the procedure to long-term management
Giustino G and Dangas G
free
Trending articles
172.05

Focus article

10.4244/EIJY19M08_01 Jan 17, 2020
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
Glikson M et al
free
42

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
26.5

Expert Review

10.4244/EIJ-D-24-00535 May 5, 2025
Catheter-based techniques for pulmonary embolism treatment
Costa F et al
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved